1. Why Late-Stage LCM Has Become a Board-Level Discipline The pharmaceutical industry is staring at its largest revenue destruction event […]
1. The Reverse Supply Chain: Scale, Scope, and Why It Landed on the CFO’s Desk The pharmaceutical forward supply chain
Executive Overview: The High-Stakes Architecture of Market Exclusivity The global pharmaceutical industry operates at the precarious intersection of intellectual property
A deep-dive reference for pharmaceutical IP teams, R&D leads, payer strategy groups, and institutional investors. Executive Summary The question of
I. Why Patent Strategy Is Really Business Strategy Here is a number worth sitting with: the U.S. pharmaceutical industry spent
Drug Patents: The Complete Playbook for Pharmaceutical Competitive Advantage Read Post »
Executive Lead: Why Emerging Markets Are the Only Game That Matters The global generic drug market will reach approximately USD
Generic Drug Entry in Emerging Markets: The $927B Patent Cliff Playbook Read Post »
Global Pharmaceutical Distribution and Patent Exclusivity: A Strategic Framework The global pharmaceutical market exceeds 1.48 trillion dollars in annual valuation.
How to Order the FDA Orange Book Historical copies of the FDA Orange Book archives are very potent tools for
Download FDA Orange Book Archives Read Post »
1. Executive Summary This report provides a comprehensive analysis of Dupixent’s (dupilumab) pricing model to assess its viability as a
How a $37,000-a-year medicine sets a good model for drug pricing Read Post »
Get fresh news and insights, drug patent expirations & more…
